Stock PHARMACYCLICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Pharmacyclics, Inc. Share Price

Equities

US7169331060

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Pharmacyclics, Inc.
2015 Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal RE
2015 Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer RE

Latest news about Pharmacyclics, Inc.

Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal RE
Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer RE
Mylan NV : Generic drugmaker Teva makes $40 billion offer for rival Mylan RE
Mylan NV : Exclusive - Perrigo expected to reject Mylan offer as soon as this week RE
Actavis : Generic drugmaker Mylan offers $29 billion for Perrigo RE
AbbVie : CEO defends Pharmacyclics deal to sceptical investors RE
Wall Street closes up slightly ahead of jobs report RE
AbbVie : CEO says new form of Humira could thwart generics RE
AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal RE
AbbVie : Biotech buys get pharma M&A off to flying start in 2015 RE
AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal RE
Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels RE
More news

Press releases Pharmacyclics, Inc.

Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma PU
Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers PU
Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent PU
Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia PU
Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe PU
More press releases

News in other languages on Pharmacyclics, Inc.

Wall Street se reprend un peu dans un climat d'attente
DJ Industrial : Wall Street se reprend un peu dans un climat d'attente
AbbVie : Début d'année en fanfare pour les fusions dans la pharmacie
AbbVie : Wall Street quasiment stable après les chiffres du chômage
Apple : Les valeurs à suivre sur les marchés américains
More news

Managers and Directors - Pharmacyclics, Inc.

Managers TitleAgeSince
Wulff-Erik von Borcke CEO
 Chief Executive Officer - 30/04/15
Betty Chang CTO
 Chief Tech/Sci/R&D Officer - 08/07/13
Heow Tan CTO
 Chief Tech/Sci/R&D Officer 65 30/04/12
More insiders

Company Profile

More about the company

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.77% 42.86B
LONZA GROUP AG Stock Lonza Group AG
+47.70% 41.36B
MODERNA, INC. Stock Moderna, Inc.
+12.24% 42.74B
CELLTRION, INC. Stock Celltrion, Inc.
-8.83% 27.68B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.44% 25.15B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.01% 18.63B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.56% 12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.82% 11.92B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.35% 11.21B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. Stock